CL2015002608A1 - Compuesto de amino-pirazol y usos medicinales relacionados. - Google Patents

Compuesto de amino-pirazol y usos medicinales relacionados.

Info

Publication number
CL2015002608A1
CL2015002608A1 CL2015002608A CL2015002608A CL2015002608A1 CL 2015002608 A1 CL2015002608 A1 CL 2015002608A1 CL 2015002608 A CL2015002608 A CL 2015002608A CL 2015002608 A CL2015002608 A CL 2015002608A CL 2015002608 A1 CL2015002608 A1 CL 2015002608A1
Authority
CL
Chile
Prior art keywords
amino
pyrazole compound
medicinal uses
related medicinal
pyrazole
Prior art date
Application number
CL2015002608A
Other languages
English (en)
Inventor
Takahisa Motomura
Gakujun Shomi
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51536938&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015002608(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of CL2015002608A1 publication Critical patent/CL2015002608A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/23—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/78—Benzoic acid esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos derivados de pirazol-amida y sus sales farmacéuticamente aceptables, como inhibidores de piruvato deshidrogenasa cinasa; composición farmacéutica que los comprende, útil para la profilaxis o tratamiento de diabetes, hiperglicemia, insuficiencia cardiaca, EPOC, entre otras enfermedades.
CL2015002608A 2013-03-15 2015-09-11 Compuesto de amino-pirazol y usos medicinales relacionados. CL2015002608A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361791164P 2013-03-15 2013-03-15
JP2013053195 2013-03-15
JP2013127318 2013-06-18

Publications (1)

Publication Number Publication Date
CL2015002608A1 true CL2015002608A1 (es) 2016-03-04

Family

ID=51536938

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015002608A CL2015002608A1 (es) 2013-03-15 2015-09-11 Compuesto de amino-pirazol y usos medicinales relacionados.

Country Status (31)

Country Link
US (4) US9040717B2 (es)
EP (3) EP3805205A1 (es)
JP (6) JP6208603B2 (es)
KR (1) KR102226096B1 (es)
CN (1) CN105051015B (es)
AU (1) AU2014230569B2 (es)
BR (1) BR112015022077A2 (es)
CA (1) CA2904985C (es)
CL (1) CL2015002608A1 (es)
CY (1) CY1120173T1 (es)
DK (1) DK2975028T3 (es)
ES (1) ES2663789T3 (es)
HK (1) HK1215808A1 (es)
HR (1) HRP20180635T1 (es)
HU (1) HUE036672T2 (es)
IL (1) IL241355B (es)
LT (1) LT2975028T (es)
ME (1) ME03090B (es)
MX (1) MX2015012743A (es)
MY (1) MY182884A (es)
NO (1) NO2975028T3 (es)
PE (1) PE20151595A1 (es)
PH (1) PH12015501993A1 (es)
PL (1) PL2975028T3 (es)
PT (1) PT2975028T (es)
RS (1) RS57188B1 (es)
RU (1) RU2664532C2 (es)
SG (1) SG11201507327TA (es)
SI (1) SI2975028T1 (es)
TW (1) TWI633885B (es)
WO (1) WO2014142290A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2649156T3 (es) 2013-01-14 2018-01-10 Incyte Holdings Corporation Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim
AR094664A1 (es) 2013-01-15 2015-08-19 Incyte Corp Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
SI2975028T1 (en) * 2013-03-15 2018-07-31 Japan Tobacco, Inc. PIRAZOL-AMIDIC COMPOUNDS AND MEDICINAL USE FORM
CN105658653A (zh) 2013-08-23 2016-06-08 因赛特公司 可用作pim激酶抑制剂的呋喃并-和噻吩并-吡啶甲酰胺化合物
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
TW201718546A (zh) 2015-10-02 2017-06-01 英塞特公司 適用作pim激酶抑制劑之雜環化合物
MX2019001228A (es) * 2016-07-29 2019-06-03 Japan Tobacco Inc Metodo de produccion del compuesto de pirazol-amida.
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
PE20211273A1 (es) * 2018-02-01 2021-07-19 Japan Tobacco Inc Compuesto de amida heterociclica nitrogenada y su uso para fines medicos
CN112638377A (zh) * 2018-09-11 2021-04-09 日本烟草产业株式会社 含有吡唑酰胺化合物的慢性肾脏病的治疗或预防剂
AU2020232630A1 (en) 2019-03-04 2021-09-16 Japan Tobacco Inc. Amorphous solid dispersion of pyrazole-amide compound
IL295836A (en) * 2020-03-04 2022-10-01 Japan Tobacco Inc A fused tricyclic compound and its medicinal use
WO2023032940A1 (ja) * 2021-09-01 2023-03-09 日本たばこ産業株式会社 含窒素三環性化合物及びその医薬用途
KR20240045387A (ko) * 2022-09-28 2024-04-08 (주)제이디바이오사이언스 신규한 플루오렌 유도체 및 이의 용도

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2827285B1 (fr) * 2001-07-10 2003-12-05 Rhodia Chimie Sa Reactif et procede pour la perfluoroalcoylation
TWI329111B (en) 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
US7098241B2 (en) 2002-12-16 2006-08-29 Hoffmann-La Roche Inc. Thiophene hydroxamic acid derivatives
DK1620118T3 (da) 2003-04-08 2014-09-29 Yeda Res & Dev Reversible pegylerede lægemidler
RU2006107371A (ru) 2004-02-20 2006-09-10 Астеллас Фарма Инк. (Jp) Флуореновые производные
FR2885904B1 (fr) 2005-05-19 2007-07-06 Aventis Pharma Sa Nouveaux derives du fluorene, compositions les contenant et utilisation
RU2007147844A (ru) * 2005-05-23 2009-06-27 Джапан Тобакко Инк. (Jp) Пиразольное соединение и содержащее его терапевтическое средство для лечения сахарного диабета
US7767685B2 (en) * 2006-06-29 2010-08-03 King Pharmaceuticals Research And Development, Inc. Adenosine A2B receptor antagonists
FR2936173B1 (fr) * 2008-09-22 2012-09-21 Snecma Procede pour la fabrication d'une piece en titane avec forgeage initial dans le domaine beta
AR074797A1 (es) * 2008-10-10 2011-02-16 Japan Tobacco Inc Compuesto de fluoreno , composiciones farmaceuticas , inhibidores de pdhk y pdhk2 , metodos de tratamiento , usos de los mismos y kit comercial
WO2010123016A1 (ja) * 2009-04-22 2010-10-28 アステラス製薬株式会社 カルボン酸化合物
AR095346A1 (es) * 2013-03-15 2015-10-07 Japan Tobacco Inc Compuesto de hidrato de fluoreno y sus cristales
SI2975028T1 (en) * 2013-03-15 2018-07-31 Japan Tobacco, Inc. PIRAZOL-AMIDIC COMPOUNDS AND MEDICINAL USE FORM
TW201536748A (zh) 2013-07-01 2015-10-01 Japan Tobacco Inc 茀－醯胺化合物及其醫藥用途
TW201536749A (zh) 2013-07-01 2015-10-01 Japan Tobacco Inc 吡唑－醇化合物及其醫藥用途

Also Published As

Publication number Publication date
JP6208603B2 (ja) 2017-10-04
TW201501711A (zh) 2015-01-16
US9040717B2 (en) 2015-05-26
DK2975028T3 (en) 2018-03-12
PL2975028T3 (pl) 2018-10-31
SI2975028T1 (en) 2018-07-31
JP2018021061A (ja) 2018-02-08
LT2975028T (lt) 2018-04-10
AU2014230569A1 (en) 2015-10-08
US20160074364A1 (en) 2016-03-17
PE20151595A1 (es) 2015-11-24
RU2015144182A3 (es) 2018-03-06
PH12015501993B1 (en) 2016-01-11
RS57188B1 (sr) 2018-07-31
EP3805205A1 (en) 2021-04-14
IL241355A0 (en) 2015-11-30
EP3348545A1 (en) 2018-07-18
CN105051015B (zh) 2018-09-25
JP2020189855A (ja) 2020-11-26
PT2975028T (pt) 2018-03-29
AU2014230569B2 (en) 2017-11-23
RU2664532C2 (ru) 2018-08-20
EP2975028A4 (en) 2016-08-17
ME03090B (me) 2019-01-20
JP2022000453A (ja) 2022-01-04
SG11201507327TA (en) 2015-10-29
CN105051015A (zh) 2015-11-11
JP2019194197A (ja) 2019-11-07
MX2015012743A (es) 2016-02-19
HUE036672T2 (hu) 2018-07-30
WO2014142290A1 (ja) 2014-09-18
IL241355B (en) 2019-03-31
RU2015144182A (ru) 2017-04-24
TWI633885B (zh) 2018-09-01
KR20150131221A (ko) 2015-11-24
US20180256547A1 (en) 2018-09-13
MY182884A (en) 2021-02-05
KR102226096B1 (ko) 2021-03-09
BR112015022077A2 (pt) 2017-07-18
CA2904985A1 (en) 2014-09-18
US20200163937A1 (en) 2020-05-28
US20140296315A1 (en) 2014-10-02
PH12015501993A1 (en) 2016-01-11
CA2904985C (en) 2021-07-20
HK1215808A1 (zh) 2016-09-15
JP2015024984A (ja) 2015-02-05
CY1120173T1 (el) 2018-12-12
EP2975028A1 (en) 2016-01-20
NO2975028T3 (es) 2018-07-21
HRP20180635T1 (hr) 2018-06-01
EP2975028B1 (en) 2018-02-21
ES2663789T3 (es) 2018-04-17
JP2018188449A (ja) 2018-11-29

Similar Documents

Publication Publication Date Title
CL2015002608A1 (es) Compuesto de amino-pirazol y usos medicinales relacionados.
NI201600058A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4
SV2015005066A (es) Compuestos de biaril-amida como inhibidores de cinasa
SV2016005137A (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
NI201600018A (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CL2015003442A1 (es) Derivados heterociclicos
DOP2013000192A (es) Compuestos y composiciones como inhibidores de la trk
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
BR112016015838A8 (pt) compostos heterocíclicos aromáticos, composição farmacêutica compreendendo os referidos compostos e produto de combinação
ECSP17013903A (es) Protein kinase c inhibitors and methods of their use
SV2018005687A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
CL2013001338A1 (es) Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih.
UY35485A (es) Compuestos heterocíclicos y usos de los mismos
AR104984A1 (es) Compuestos selectivos para pyy y sus usos
SV2017005405A (es) Compuestos y composiciones como inhibidores de quinasa raf
CL2015000744A1 (es) Combinación de regorafenib y ácido acetilsalicílico para el tratamiento del cáncer.
CU20160192A7 (es) Derivados de indano e indolina útiles como activadores de la guanilato ciclasa soluble
CL2015001279A1 (es) Compuestos derivados de piridina, inhibidores del transportador de uratos urat 1; composicion farmaceutica que los comprende; uso para el tratamiento o prevencion de enfermedades tales como gota, hiperuricemia, hipertensión, enfermedades renales, entre otras.
DOP2015000170A (es) Compuestos químicos
CL2015000615A1 (es) Compuestos derivados de 4-amino-quinolinas, inhibidores de rip2 cinasa; composicion farmaceutica que los comprende; uso para el tratamiento de enfermedades tales como enfermedad de crohn, colitis ulcerativa o sindrome de blau.
BR112017016817A2 (pt) derivados heterocíclicos formilados como inibidores de fgfr4
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
SV2016005313A (es) Derivados de carboxamida
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel